Braidwell »

Fulcrum Therapeutics shares owned by Braidwell

Quarter-by-quarter ownership of Fulcrum Therapeutics (FULC) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Fulcrum Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Fulcrum Therapeutics held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fulcrum Therapeutics by Braidwell

Quarter filed Position value Share count Share price at filing
2024-09-30 $3.8M 1.1M 3.57

More positions owned by Braidwell

Guardant Health Note11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Novocure Note11/0 (Principal)
Cg Oncology (CGON)
Nuvasive Note 0.375% 3/1 (Principal)
Xenon Pharmaceuticals (XENE)
Neurocrine Biosciences (NBIX)
Neogenomics Note 0.250% 1/1 (Principal)
Apogee Therapeutics (APGE)
Apellis Pharmaceuticals (APLS)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Dexcom Note 0.375% 5/1 (Principal)
Align Technology (ALGN)
Guardant Health (GH)
Insulet Corp Note 0.375% 9/0 (Principal)

View all positions for Braidwell

Top funds holding Fulcrum Therapeutics

RA Capital Management
BlackRock
BlackRock
Nantahala Capital Management
Caption Management
Vanguard Group
Suvretta Capital Management
Trv Gp Iv
Citadel Advisors
Perceptive Advisors
Logos Global Management
MPM Oncology Impact Management
Leucadia National Corporation
Dimensional Fund Advisors
Geode Capital Management

View all funds holding Fulcrum Therapeutics